The EPA3G branded dietary supplement is available in sachet form and contains almost three grams of the omega-3 oil eicosapentaenoic acid (EPA), which can be administered as a drinkable emulsion once a day.
According to the company, the format overcomes current problems with omega-3 consumption, such as the dosage required to achieve significant health benefits and the lack of alternatives to bulky, hard-to-swallow capsules.
“With this agreement, people now have a differentiated, value-added omega-3 product that is effective and easy to use,” said Luciano Conde, CEO of Noventure.
“We are very happy to work with Azur. Together we will continue to build strong partnerships based on a shared understanding of user needs and pursue market opportunities as we grow together. “
EPA and DHA market
The agreement stipulates that Noventure will acquire the rights to license EPA3G to companies with “marketing expertise and knowledge in the marketing of high-quality nutritional supplements”.
Noventure may exercise these license rights for all EU members and associated countries, Great Britain, the Balkans, Russia, Ukraine, Eurasian countries, Mexico, Taiwan and several African countries. Financial terms of the agreement were not disclosed.
Regarding the expected growth of the global EPA and DHA market of 8.26% in the period 2020-2025, Julio Boza, CEO of Azur, cites the reasons for this growth to the “increased prevalence of lifestyle diseases and people who are decide preventive health measures.
“Consumer desire for high potency and bioavailability has also caused manufacturers to look for more concentrated forms to provide more effective doses of EPA. We look forward to working with Noventure.
We believe this technology will enable people to get their omega-3 needs in a convenient, drinkable format. This is a great example of transforming smart science and technology into groundbreaking, sustainable commercial solutions and an example of how to work together and grow together. “